Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Stock Has Average Target Price of $53.00 According to Brokerages

Posted by Francis Steltz on Nov 11th, 2026

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Get Free Report) have earned a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $53.00.

A number of equities research analysts have weighed in on the stock. TD Cowen upgraded shares of Immunocore to a “strong-buy” rating in a research note on Monday, August 24th. Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 3rd. HC Wainwright cut their price target on Immunocore from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday. Mizuho increased their price objective on shares of Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, October 15th.

Get Our Latest Stock Analysis on IMCR

Immunocore Trading Up 2.0%

NASDAQ:IMCR opened at $32.38 on Wednesday. The company has a current ratio of 4.62, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. Immunocore has a 12 month low of $27.50 and a 12 month high of $40.71. The company has a 50-day moving average price of $31.46 and a 200-day moving average price of $31.70. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -49.81 and a beta of 0.82.

Immunocore (NASDAQ:IMCR – Get Free Report) last announced its earnings results on Friday, November 6th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The business had revenue of $102.22 million for the quarter, compared to the consensus estimate of $152.09 million. Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. Equities analysts predict that Immunocore will post -0.04 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. GAMMA Investing LLC increased its stake in Immunocore by 202.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $61,000 after buying an additional 1,286 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Immunocore in the 3rd quarter worth approximately $72,000. Juncture Wealth Strategies LLC purchased a new stake in Immunocore during the 3rd quarter valued at approximately $207,000. denkapparat Operations GmbH purchased a new stake in Immunocore during the 2nd quarter valued at approximately $209,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Immunocore by 27.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,252 shares of the company’s stock valued at $285,000 after buying an additional 1,975 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.